---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-039211"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2023-11-16T23:59:59+00:00"
generated_at: "2026-06-08T01:08:39.507353+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nasdaq grants Avalo Therapeutics extension to Dec 29 to regain $1 bid price

## Summary
- Received Nasdaq notice on Nov 14, 2023 of Panel granting exception from MVLS and bid price rules until Dec 29, 2023.
- Condition 1 already met: Company filed Form 10-Q on Nov 9 showing stockholders' equity of $14.7M, satisfying Nasdaq equity requirement.
- Condition 2: Must maintain closing bid price of $1.00 for ten consecutive sessions by Dec 29 to avoid delisting.
- Previously, on Sep 13, Nasdaq notified Company of low-priced stock rule due to bid price <=$0.10 for ten consecutive days.
- No assurance of regaining compliance; risk of delisting remains.

## SEC filing metadata
- accession: 0001628280-23-039211
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2023-11-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/0001628280-23-039211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/avtx-20231114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-039211
- JSON: https://secwatch.observer/filing/0001628280-23-039211.json
- Plain text: https://secwatch.observer/filing/0001628280-23-039211.txt

## Key facts
- Listing & Compliance Notices
  Avalo Therapeutics, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2), 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: hearing update
  - Deficiency: minimum bid price
  - Rules: 5810(c)(3)(A)(iii), 5550(a)(2), 5550(b)(1)
  source text: November 14, 2023, the Company received written notice from Nasdaq (the “November Notification Letter”) that the Panel had granted the Company an exception from compliance with the MVLS Rule and the Bid Price Rule and extension of continued listing until December 29, 2023, subject to the following: 1. On or before November 9, 2023, the Company will demonstrate compliance with Listing Rule 5550(b)(1) by filing its Form 10-Q with the SEC evidencing a minimum of $2.5million in stockholders’ equity; and 2. On or before December 29, 2023, the Company will demonstrate compliance with Listing Rule 55
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/0001628280-23-039211-index.htm
- Listing & Compliance Notices
  Avalo Therapeutics, Inc. received a nasdaq hearing update notice regarding market value (rules 5550(b)(2), 5810(c)(3)(A), 5810(c)(3)(C)).
  - Exchange: nasdaq
  - Notice: hearing update
  - Deficiency: market value
  - Rules: 5550(b)(2), 5810(c)(3)(A), 5810(c)(3)(C)
  source text: November 14, 2023, the Company received written notice from Nasdaq (the “November Notification Letter”) that the Panel had granted the Company an exception from compliance with the MVLS Rule and the Bid Price Rule and extension of continued listing until December 29, 2023, subject to the following: 1. On or before November 9, 2023, the Company will demonstrate compliance with Listing Rule 5550(b)(1) by filing its Form 10-Q with the SEC evidencing a minimum of $2.5million in stockholders’ equity; and 2. On or before December 29, 2023, the Company will demonstrate compliance with Listing Rule 55
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828023039211/0001628280-23-039211-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.